Exercise Benefits Patients Being Treated for Early-Stage Breast Cancer

OncologyONCOLOGY Vol 15 No 5
Volume 15
Issue 5

Contrary to traditional medical advice that rest is the best medicine for fatigue caused by treatment for breast cancer, the largest study of its kind found that exercise improves physical functioning and weight control for many patients.

Contrary to traditional medical advice that rest isthe best medicine for fatigue caused by treatmentfor breast cancer, the largest study of its kind found that exercise improvesphysical functioning and weight control for many patients. Researchers in Canadafound that women undergoing treatment for early-stage breast cancer whomaintained a regular exercise program of hour-long walking sessions 3 to 5 timesper week for 6 months had a significant improvement in cardiac conditioningand overall functioning.

As reported in the Journal of Clinical Oncology (19:657-665,2001), the randomized study of 123 patients concluded that women who exercisedon their own in a "self-directed" exercise program increased physicalfunctioning by 5.7 points on a standard scale of 100 points, and those whoexercised in supervised groups gained 2.2 points in functioning.Comparatively, researchers found that inactivity contributed to the debilitationof patients in a control group who followed the traditional medical advice oflittle or no exercise during cancer treatment—this group actually lost anaverage of 4.1 points in their physical functioning. The findings wereconsistent across all patient subgroups, whether they received chemotherapy,hormonal treatments, or radiation therapy.

"Breast cancer patients receiving adjuvant therapy,including chemotherapy, are willing, and quite capable, of participating inexercise. Even moderate physical activity was meaningful, resulting in anincreased ability to function and feel independent," said the study’slead author, Roanne Segal, MD, medical director of the oncology rehabilitationprogram at Ottawa Regional Cancer Centre.

Surprising Finding

The investigators were surprised to find that women whoexercised on their own had better aerobic results than women who participated ina group-supervised exercise program. The difference, Dr. Segal speculated, couldbe attributable to the fact that patients who exercised within a medical settingwere more restrained, compared to women who exercised as they liked at home.

In addition, she pointed out that patients who were usingtamoxifen (Nolvadex) as hormonal therapy, which can increase weight in somewomen, had the greatest weight reduction of all participants following exercise—anaverage of 2 to 8 lb.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content